Elevated sHLA-G plasma levels post chemotherapy combined with ILT-2 rs10416697C allele status of the sHLA-G-related receptor predict poorest disease outcome in early triple-negative breast cancer patients
IntroductionTriple negative breast cancer (TNBC) shows an aggressive growing and spreading behavior and has limited treatment options, often leading to inferior disease outcome. Therefore, surrogate markers are urgently needed to identify patients at high risk of recurrence and more importantly, to...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1188030/full |
| _version_ | 1797822517507784704 |
|---|---|
| author | Oliver Hoffmann Oliver Hoffmann Sebastian Wormland Ann-Kathrin Bittner Ann-Kathrin Bittner Julian Hölzenbein Esther Schwich Sabine Schramm Hana Rohn Peter A. Horn Rainer Kimmig Rainer Kimmig Sabine Kasimir-Bauer Sabine Kasimir-Bauer Vera Rebmann |
| author_facet | Oliver Hoffmann Oliver Hoffmann Sebastian Wormland Ann-Kathrin Bittner Ann-Kathrin Bittner Julian Hölzenbein Esther Schwich Sabine Schramm Hana Rohn Peter A. Horn Rainer Kimmig Rainer Kimmig Sabine Kasimir-Bauer Sabine Kasimir-Bauer Vera Rebmann |
| author_sort | Oliver Hoffmann |
| collection | DOAJ |
| description | IntroductionTriple negative breast cancer (TNBC) shows an aggressive growing and spreading behavior and has limited treatment options, often leading to inferior disease outcome. Therefore, surrogate markers are urgently needed to identify patients at high risk of recurrence and more importantly, to identify additional therapeutic targets enabling further treatment options. Based on the key role of the non-classical human leukocyte antigen G (HLA-G) and its related receptor immunoglobulin-like transcript receptor-2 (ILT-2) in immune evasion mechanisms of tumors, members of this ligand-receptor axis appear to be promising tool for both, defining risk groups and potential therapeutic targets.Materials and methodsTo follow this, sHLA-G levels before and after chemotherapy (CT), HLA-G 3’ UTR haplotypes, and allele variations rs10416697 at the distal gene promoter region of ILT-2 were defined in healthy female controls and early TNBC patients. The results obtained were associated with clinical status, presence of circulating tumor cell (CTC) subtypes, and disease outcome of patients in terms of progression-free or overall survival.ResultssHLA-G plasma levels were increased in TNBC patients post-CT compared to levels of patients pre-CT or controls. High post-CT sHLA-G levels were associated with the development of distant metastases, the presence of ERCC1 or PIK3CA-CTC subtypes post-CT, and poorer disease outcome in uni- or multivariate analysis. HLA-G 3’ UTR genotypes did not influence disease outcome but ILT-2 rs10416697C allele was associated with AURKA-positive CTC and with adverse disease outcome by uni- and multivariate analysis. The prognostic value of the combined risk factors (high sHLA-G levels post-CT and ILT-2 rs10416697C allele carrier status) was an even better independent indicator for disease outcome in TNBC than the lymph nodal status pre-CT. This combination allowed the identification of patients with high risk of early progression/death with positive nodal status pre-CT or with non-pathological complete therapy responseConclusionThe results of this study highlight for the first time that the combination of high levels of sHLA-G post-CT with ILT-2 rs10416697C allele receptor status is a promising tool for the risk assessment of TNBC patients and support the concept to use HLA-G/ILT-2 ligand-receptor axis as therapeutic targets. |
| first_indexed | 2024-03-13T10:10:14Z |
| format | Article |
| id | doaj.art-1b610616dd9c4983a9d9f684f293205d |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-13T10:10:14Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-1b610616dd9c4983a9d9f684f293205d2023-05-22T04:42:40ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-05-011410.3389/fimmu.2023.11880301188030Elevated sHLA-G plasma levels post chemotherapy combined with ILT-2 rs10416697C allele status of the sHLA-G-related receptor predict poorest disease outcome in early triple-negative breast cancer patientsOliver Hoffmann0Oliver Hoffmann1Sebastian Wormland2Ann-Kathrin Bittner3Ann-Kathrin Bittner4Julian Hölzenbein5Esther Schwich6Sabine Schramm7Hana Rohn8Peter A. Horn9Rainer Kimmig10Rainer Kimmig11Sabine Kasimir-Bauer12Sabine Kasimir-Bauer13Vera Rebmann14Department of Gynecology and Obstetrics, University Hospital of Essen, Essen, GermanyNational Center for Tumor Diseases (NCT), NCT West, Essen, GermanyInstitute for Transfusion Medicine, University Hospital Essen, Essen, GermanyDepartment of Gynecology and Obstetrics, University Hospital of Essen, Essen, GermanyNational Center for Tumor Diseases (NCT), NCT West, Essen, GermanyInstitute for Transfusion Medicine, University Hospital Essen, Essen, GermanyInstitute for Transfusion Medicine, University Hospital Essen, Essen, GermanyNational Center for Tumor Diseases (NCT), NCT West, Essen, GermanyDepartment of Infection Diseases, West German Centre of Infection Diseases, University Hospital of Essen, Essen, GermanyInstitute for Transfusion Medicine, University Hospital Essen, Essen, GermanyDepartment of Gynecology and Obstetrics, University Hospital of Essen, Essen, GermanyNational Center for Tumor Diseases (NCT), NCT West, Essen, GermanyDepartment of Gynecology and Obstetrics, University Hospital of Essen, Essen, GermanyNational Center for Tumor Diseases (NCT), NCT West, Essen, GermanyInstitute for Transfusion Medicine, University Hospital Essen, Essen, GermanyIntroductionTriple negative breast cancer (TNBC) shows an aggressive growing and spreading behavior and has limited treatment options, often leading to inferior disease outcome. Therefore, surrogate markers are urgently needed to identify patients at high risk of recurrence and more importantly, to identify additional therapeutic targets enabling further treatment options. Based on the key role of the non-classical human leukocyte antigen G (HLA-G) and its related receptor immunoglobulin-like transcript receptor-2 (ILT-2) in immune evasion mechanisms of tumors, members of this ligand-receptor axis appear to be promising tool for both, defining risk groups and potential therapeutic targets.Materials and methodsTo follow this, sHLA-G levels before and after chemotherapy (CT), HLA-G 3’ UTR haplotypes, and allele variations rs10416697 at the distal gene promoter region of ILT-2 were defined in healthy female controls and early TNBC patients. The results obtained were associated with clinical status, presence of circulating tumor cell (CTC) subtypes, and disease outcome of patients in terms of progression-free or overall survival.ResultssHLA-G plasma levels were increased in TNBC patients post-CT compared to levels of patients pre-CT or controls. High post-CT sHLA-G levels were associated with the development of distant metastases, the presence of ERCC1 or PIK3CA-CTC subtypes post-CT, and poorer disease outcome in uni- or multivariate analysis. HLA-G 3’ UTR genotypes did not influence disease outcome but ILT-2 rs10416697C allele was associated with AURKA-positive CTC and with adverse disease outcome by uni- and multivariate analysis. The prognostic value of the combined risk factors (high sHLA-G levels post-CT and ILT-2 rs10416697C allele carrier status) was an even better independent indicator for disease outcome in TNBC than the lymph nodal status pre-CT. This combination allowed the identification of patients with high risk of early progression/death with positive nodal status pre-CT or with non-pathological complete therapy responseConclusionThe results of this study highlight for the first time that the combination of high levels of sHLA-G post-CT with ILT-2 rs10416697C allele receptor status is a promising tool for the risk assessment of TNBC patients and support the concept to use HLA-G/ILT-2 ligand-receptor axis as therapeutic targets.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1188030/fulltriple-negative breast cancerearly breast cancer (EBC)biomarkerILT-2 rs10416697C allelesHLA-GCTC (circulation tumor cells) |
| spellingShingle | Oliver Hoffmann Oliver Hoffmann Sebastian Wormland Ann-Kathrin Bittner Ann-Kathrin Bittner Julian Hölzenbein Esther Schwich Sabine Schramm Hana Rohn Peter A. Horn Rainer Kimmig Rainer Kimmig Sabine Kasimir-Bauer Sabine Kasimir-Bauer Vera Rebmann Elevated sHLA-G plasma levels post chemotherapy combined with ILT-2 rs10416697C allele status of the sHLA-G-related receptor predict poorest disease outcome in early triple-negative breast cancer patients Frontiers in Immunology triple-negative breast cancer early breast cancer (EBC) biomarker ILT-2 rs10416697C allele sHLA-G CTC (circulation tumor cells) |
| title | Elevated sHLA-G plasma levels post chemotherapy combined with ILT-2 rs10416697C allele status of the sHLA-G-related receptor predict poorest disease outcome in early triple-negative breast cancer patients |
| title_full | Elevated sHLA-G plasma levels post chemotherapy combined with ILT-2 rs10416697C allele status of the sHLA-G-related receptor predict poorest disease outcome in early triple-negative breast cancer patients |
| title_fullStr | Elevated sHLA-G plasma levels post chemotherapy combined with ILT-2 rs10416697C allele status of the sHLA-G-related receptor predict poorest disease outcome in early triple-negative breast cancer patients |
| title_full_unstemmed | Elevated sHLA-G plasma levels post chemotherapy combined with ILT-2 rs10416697C allele status of the sHLA-G-related receptor predict poorest disease outcome in early triple-negative breast cancer patients |
| title_short | Elevated sHLA-G plasma levels post chemotherapy combined with ILT-2 rs10416697C allele status of the sHLA-G-related receptor predict poorest disease outcome in early triple-negative breast cancer patients |
| title_sort | elevated shla g plasma levels post chemotherapy combined with ilt 2 rs10416697c allele status of the shla g related receptor predict poorest disease outcome in early triple negative breast cancer patients |
| topic | triple-negative breast cancer early breast cancer (EBC) biomarker ILT-2 rs10416697C allele sHLA-G CTC (circulation tumor cells) |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1188030/full |
| work_keys_str_mv | AT oliverhoffmann elevatedshlagplasmalevelspostchemotherapycombinedwithilt2rs10416697callelestatusoftheshlagrelatedreceptorpredictpoorestdiseaseoutcomeinearlytriplenegativebreastcancerpatients AT oliverhoffmann elevatedshlagplasmalevelspostchemotherapycombinedwithilt2rs10416697callelestatusoftheshlagrelatedreceptorpredictpoorestdiseaseoutcomeinearlytriplenegativebreastcancerpatients AT sebastianwormland elevatedshlagplasmalevelspostchemotherapycombinedwithilt2rs10416697callelestatusoftheshlagrelatedreceptorpredictpoorestdiseaseoutcomeinearlytriplenegativebreastcancerpatients AT annkathrinbittner elevatedshlagplasmalevelspostchemotherapycombinedwithilt2rs10416697callelestatusoftheshlagrelatedreceptorpredictpoorestdiseaseoutcomeinearlytriplenegativebreastcancerpatients AT annkathrinbittner elevatedshlagplasmalevelspostchemotherapycombinedwithilt2rs10416697callelestatusoftheshlagrelatedreceptorpredictpoorestdiseaseoutcomeinearlytriplenegativebreastcancerpatients AT julianholzenbein elevatedshlagplasmalevelspostchemotherapycombinedwithilt2rs10416697callelestatusoftheshlagrelatedreceptorpredictpoorestdiseaseoutcomeinearlytriplenegativebreastcancerpatients AT estherschwich elevatedshlagplasmalevelspostchemotherapycombinedwithilt2rs10416697callelestatusoftheshlagrelatedreceptorpredictpoorestdiseaseoutcomeinearlytriplenegativebreastcancerpatients AT sabineschramm elevatedshlagplasmalevelspostchemotherapycombinedwithilt2rs10416697callelestatusoftheshlagrelatedreceptorpredictpoorestdiseaseoutcomeinearlytriplenegativebreastcancerpatients AT hanarohn elevatedshlagplasmalevelspostchemotherapycombinedwithilt2rs10416697callelestatusoftheshlagrelatedreceptorpredictpoorestdiseaseoutcomeinearlytriplenegativebreastcancerpatients AT peterahorn elevatedshlagplasmalevelspostchemotherapycombinedwithilt2rs10416697callelestatusoftheshlagrelatedreceptorpredictpoorestdiseaseoutcomeinearlytriplenegativebreastcancerpatients AT rainerkimmig elevatedshlagplasmalevelspostchemotherapycombinedwithilt2rs10416697callelestatusoftheshlagrelatedreceptorpredictpoorestdiseaseoutcomeinearlytriplenegativebreastcancerpatients AT rainerkimmig elevatedshlagplasmalevelspostchemotherapycombinedwithilt2rs10416697callelestatusoftheshlagrelatedreceptorpredictpoorestdiseaseoutcomeinearlytriplenegativebreastcancerpatients AT sabinekasimirbauer elevatedshlagplasmalevelspostchemotherapycombinedwithilt2rs10416697callelestatusoftheshlagrelatedreceptorpredictpoorestdiseaseoutcomeinearlytriplenegativebreastcancerpatients AT sabinekasimirbauer elevatedshlagplasmalevelspostchemotherapycombinedwithilt2rs10416697callelestatusoftheshlagrelatedreceptorpredictpoorestdiseaseoutcomeinearlytriplenegativebreastcancerpatients AT verarebmann elevatedshlagplasmalevelspostchemotherapycombinedwithilt2rs10416697callelestatusoftheshlagrelatedreceptorpredictpoorestdiseaseoutcomeinearlytriplenegativebreastcancerpatients |